Revenue
2021
2022
2023
2024
2025
Kiniksa Pharmaceuticals International, plc (KNSA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — | — |
| Research & development | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M | $112.0M | $135.0M | $86.6M | $56.4M |
| Operating expenses | — | — | — | — | — | $157.4M | $170.0M | $108.2M | $65.4M |
| Operating income | $77.2M | −$45.6M | −$25.2M | $9.8M | −$156.6M | −$157.4M | −$170.0M | −$108.2M | −$65.4M |
| EBITDAderived | $78.8M | −$43.9M | −$22.9M | $12.2M | −$154.3M | −$155.0M | −$167.9M | — | — |
| Net income | $59.0M | −$43.2M | $14.1M | $183.4M | −$157.9M | −$161.4M | −$161.9M | −$103.2M | −$64.9M |
| Basic EPSper diluted share | $0.80 | -$0.60 | $0.20 | $2.64 | -$2.30 | -$2.61 | -$2.99 | -$3.49 | -$35.85 |
| Diluted EPSper diluted share | $0.75 | -$0.60 | $0.20 | $2.60 | -$2.30 | -$2.61 | -$2.99 | -$3.49 | -$35.85 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2026Form 4 · 10b5-1 | Paolini John F.CHIEF MEDICAL OFFICER | SellClass A Ordinary Share | 21.1K | $54.04 | $1.14M | 65.6K |
| May 1, 2026Form 4 · 10b5-1 | Paolini John F.CHIEF MEDICAL OFFICER | SellClass A Ordinary Share | 37.3K | $53.52 | $2.00M | 86.7K |
| May 1, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 48.6K | $54.02 | $2.62M | 0 |
| Apr 30, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 2.1K | $54.01 | $115.6K | 0 |
| Apr 29, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 22.5K | $54.01 | $1.22M | 0 |